Metabolic disorders and the risk of COVID-19

Karaseva, A. A.; Khudyakova, A. D.; Ragino, Yu. I.

doi:10.18699/ssmj20220101

Our system is currently under heavy load due to increased usage. We're actively working on upgrades to improve performance. Thank you for your patience.

Sibirskij nauchnyj medicinskij zhurnal

2022

DOI: 10.18699/ssmj20220101

|View full text |Cite

Metabolic disorders and the risk of COVID-19

A. A. Karaseva

A. D. Khudyakova

Yu. I. Ragino

Abstract: Целью настоящего обзора является анализ данных научной медицинской мировой литературы, посвященной изучению нарушений метаболизма и риска заболевания COVID-19. Известно, что метаболический синдром является независимым фактором риска тяжелого течения новой коронавирусной инфекции. В обзоре обобщены данные о механизмах метаболической дисфункции при COVID-19, проанализированы результаты исследований, в которых изучены вопросы ассоциаций между течением заболевания и различными метаболическими нарушениями, такими к… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Development of Microcapsules Based on Combined Antidiabetic Substance: Pharmacological Characteristics

Giyoszoda¹,

Степанова

Veselova

et al. 2022

Farm. farmakol. (Pâtigorsk)

View full text Add to dashboard Cite

The comparative assessment results of the hypoglycemic activity of a combined preparation containing microcapsules with a phytocomposition consisting of Glycyrrhiza glabra L. extracts, a dry extract of Galega officinalis L., Mentha piperita L., and gliclazide, are discussed in the article. Methods for obtaining microcapsules with an original PEG-6000 shell are described.The aim of the study was to develop an optimal technology for obtaining microcapsules with a PEG-6000 shell containing a combined antidiabetic substance, and conduct its detailed pharmacological study on the model of type 2 diabetes mellitus, to conduct a detailed comparative pharmacological study of a microencapsulated antidiabetic composition with a shell based on PEG-6000, including gliclazide and a sum of phytoextracts on the model of type 2 diabetes mellitus.Materials and methods. As the main objects of the study, microcapsules with a PEG-6000 shell were obtained using methyl miristate as the base liquid. The capsules contained the amount of plant extracts in their composition: a dry extract of Glycyrrhiza glabra L., a dry extract of Galega officinalis L., a dry extract of Mentha piperita L., and gliclazide. The study of a hypoglycemic activity was carried out after a single administration of drugs to the animals with alloxan-induced type 2 diabetes mellitus. The cumulative effect assessment of the drugs was carried out within 14 days with a test for the resistance to oral glucose on days 7 and 14.Results. Microcapsules with the original shell were obtained by dispersion in a liquid-liquid system with the adjustment of some technological stages. The effect of the drugs under study on the glycemic profile in the rats with an experimental model of type 2 diabetes mellitus was investigated. A comparative evaluation of the pharmacological effect was carried out with a separate and combined use of microencapsulated preparations.Conclusion. The rationality of combining phytocomponents and a synthetic antidiabetic agent in microcapsules has been proven. The obtained results testify to the rationality of plant extracts combination and a synthetic hypoglycemic agent – gliclazide in microcapsules.

show abstract

Development of Microcapsules Based on Combined Antidiabetic Substance: Pharmacological Characteristics

Giyoszoda¹,

Степанова

Veselova

et al. 2022

Farm. farmakol. (Pâtigorsk)

View full text Add to dashboard Cite

show abstract

Prognostic Factors Associated with the Severe Course of a New Coronavirus Infection

Khamanova,

Frayfeld,

Mullagalieva

et al. 2024

Урал. мед. журнал

View full text Add to dashboard Cite

Introduction. Novel coronavirus infection (COVID-19) is a respiratory infectious disease caused by the novel severe acute respiratory syndrome 2 coronavirus (SARS-CoV-2). It is characterized by a heterogeneous course of the disease from asymptomatic and mild forms to more severe and fatal outcomes. There are many risk factors for a severe course of a new coronavirus infection, in most cases, a severe course of the disease is associated with the individual characteristics of the patient, especially with dysregulation of the immune response. In this article, we reviewed the main prognostic factors for the severity of the disease.The aim of the study is to determine the unfavorable prognostic factors associated with the severe course of a new coronavirus infection caused by the SARS-CoV-2 virus in foreign and domestic literature sources.Materials and methods. To achieve this goal, scientific publications on the new coronavirus infection caused by the SARS-CoV-2 virus were analyzed in the scientometric databases PubMed, National Center for Biotechnological Information (NCBI), Cochrane, Web of Science, Scopus, MEDLINE (2019–2022), and Russian specialized journals on infectious diseases (2019–2022). Particular attention was paid to factors influencing the severe course of a new coronavirus infection.Results. Risk factors for a severe course of a new coronavirus infection include: lipid spectrum, advanced age, hemostasis system, changes in the leukocyte count, serum markers. Mathematical models of the course of a new coronavirus infection have also been developed.Discussion. In most studies, scientists note that the uncontrolled course of COVID-19 disease is associated with a dysregulated immune response. One of the main methods of influencing the immune system is vaccination.Conclusion. There are many factors that contribute to the development of severe forms of the disease of a new coronavirus infection. However, thanks to universal vaccination against a new coronavirus infection, the frequency of severe forms of the disease and deaths has significantly decreased. Novel coronavirus infection (COVID-19) is a respiratory infectious disease caused by the novel severe acute respiratory syndrome 2 coronavirus (SARS-CoV-2).

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Metabolic disorders and the risk of COVID-19

Cited by 2 publications

References 63 publications

Development of Microcapsules Based on Combined Antidiabetic Substance: Pharmacological Characteristics

Development of Microcapsules Based on Combined Antidiabetic Substance: Pharmacological Characteristics

Prognostic Factors Associated with the Severe Course of a New Coronavirus Infection

Contact Info

Product

Resources

About